Mesenchymal chondrosarcoma

Clinicopathologic study of 20 cases

Rachel J. Shakked, David S. Geller, Richard Gorlick, Howard D. Dorfman

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Context.-Mesenchymal chondrosarcoma is a rare, highgrade malignancy of bone or soft tissue with a unique, biphasic histology and poor prognosis. Because of its rarity and variable length of disease-free survival, the natural history of the disease remains poorly understood. Objective.-To present clinical, radiographic, and histopathologic features of mesenchymal chondrosarcoma from one of the largest case series collected by a single, senior-level bone pathologist. Design.-Twenty cases were reviewed in consultations spanning 45 years. Results.-Eighteen tumors (90%) originated in bone, and 2 tumors (10%) were of extraskeletal origin. Of the skeletal tumors, locations included craniofacial bones (n = 9; 50%), ribs and chest wall (n = 4; 22%), sacrum and spinal elements (n = 3; 17%), and lower extremities (n = 2; 11%), whereas soft tissue tumors were located about the scapula (n = 1; 50%) and lower extremity (n = 1; 50%). Plain radiographs demonstrated calcified, osteolytic lesions with extraosseous extension. Typical histologic features were identified consisting of small, round or spindled cells, interspersed with hyaline cartilage islands. Seventeen patients (85%) were treated surgically, and 8 patients (40%) received adjuvant treatment. Seven patients (35%) were living at last follow-up, 1.8 to 12.5 years after diagnosis, and 8 patients (40%) died between 1.2 and 21.8 years after diagnosis. Conclusions.-Mesenchymal chondrosarcoma presents multiple challenges. Diagnostic pitfalls include inadequate biopsy samples, which may result in sample error. Sox9 has been proposed as a unique marker for mesenchymal chondrosarcoma which may improve diagnostic specificity. Treatment and prognosis vary considerably. Patients who receive surgery and chemotherapy seem to fare better. Multicenter studies with higher sample numbers may improve our understanding of this malignancy.

Original languageEnglish (US)
Pages (from-to)61-75
Number of pages15
JournalArchives of Pathology and Laboratory Medicine
Volume136
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Mesenchymal Chondrosarcoma
Bone and Bones
Neoplasms
Lower Extremity
Hyaline Cartilage
Sacrum
Scapula
Thoracic Wall
Ribs
Multicenter Studies
Disease-Free Survival
Histology
Referral and Consultation
Biopsy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Mesenchymal chondrosarcoma : Clinicopathologic study of 20 cases. / Shakked, Rachel J.; Geller, David S.; Gorlick, Richard; Dorfman, Howard D.

In: Archives of Pathology and Laboratory Medicine, Vol. 136, No. 1, 01.2012, p. 61-75.

Research output: Contribution to journalArticle

Shakked, Rachel J. ; Geller, David S. ; Gorlick, Richard ; Dorfman, Howard D. / Mesenchymal chondrosarcoma : Clinicopathologic study of 20 cases. In: Archives of Pathology and Laboratory Medicine. 2012 ; Vol. 136, No. 1. pp. 61-75.
@article{abc4aeb33fa944cba8e0b5d6dad5ecfd,
title = "Mesenchymal chondrosarcoma: Clinicopathologic study of 20 cases",
abstract = "Context.-Mesenchymal chondrosarcoma is a rare, highgrade malignancy of bone or soft tissue with a unique, biphasic histology and poor prognosis. Because of its rarity and variable length of disease-free survival, the natural history of the disease remains poorly understood. Objective.-To present clinical, radiographic, and histopathologic features of mesenchymal chondrosarcoma from one of the largest case series collected by a single, senior-level bone pathologist. Design.-Twenty cases were reviewed in consultations spanning 45 years. Results.-Eighteen tumors (90{\%}) originated in bone, and 2 tumors (10{\%}) were of extraskeletal origin. Of the skeletal tumors, locations included craniofacial bones (n = 9; 50{\%}), ribs and chest wall (n = 4; 22{\%}), sacrum and spinal elements (n = 3; 17{\%}), and lower extremities (n = 2; 11{\%}), whereas soft tissue tumors were located about the scapula (n = 1; 50{\%}) and lower extremity (n = 1; 50{\%}). Plain radiographs demonstrated calcified, osteolytic lesions with extraosseous extension. Typical histologic features were identified consisting of small, round or spindled cells, interspersed with hyaline cartilage islands. Seventeen patients (85{\%}) were treated surgically, and 8 patients (40{\%}) received adjuvant treatment. Seven patients (35{\%}) were living at last follow-up, 1.8 to 12.5 years after diagnosis, and 8 patients (40{\%}) died between 1.2 and 21.8 years after diagnosis. Conclusions.-Mesenchymal chondrosarcoma presents multiple challenges. Diagnostic pitfalls include inadequate biopsy samples, which may result in sample error. Sox9 has been proposed as a unique marker for mesenchymal chondrosarcoma which may improve diagnostic specificity. Treatment and prognosis vary considerably. Patients who receive surgery and chemotherapy seem to fare better. Multicenter studies with higher sample numbers may improve our understanding of this malignancy.",
author = "Shakked, {Rachel J.} and Geller, {David S.} and Richard Gorlick and Dorfman, {Howard D.}",
year = "2012",
month = "1",
doi = "10.5858/arpa.2010-0362-OA",
language = "English (US)",
volume = "136",
pages = "61--75",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "1",

}

TY - JOUR

T1 - Mesenchymal chondrosarcoma

T2 - Clinicopathologic study of 20 cases

AU - Shakked, Rachel J.

AU - Geller, David S.

AU - Gorlick, Richard

AU - Dorfman, Howard D.

PY - 2012/1

Y1 - 2012/1

N2 - Context.-Mesenchymal chondrosarcoma is a rare, highgrade malignancy of bone or soft tissue with a unique, biphasic histology and poor prognosis. Because of its rarity and variable length of disease-free survival, the natural history of the disease remains poorly understood. Objective.-To present clinical, radiographic, and histopathologic features of mesenchymal chondrosarcoma from one of the largest case series collected by a single, senior-level bone pathologist. Design.-Twenty cases were reviewed in consultations spanning 45 years. Results.-Eighteen tumors (90%) originated in bone, and 2 tumors (10%) were of extraskeletal origin. Of the skeletal tumors, locations included craniofacial bones (n = 9; 50%), ribs and chest wall (n = 4; 22%), sacrum and spinal elements (n = 3; 17%), and lower extremities (n = 2; 11%), whereas soft tissue tumors were located about the scapula (n = 1; 50%) and lower extremity (n = 1; 50%). Plain radiographs demonstrated calcified, osteolytic lesions with extraosseous extension. Typical histologic features were identified consisting of small, round or spindled cells, interspersed with hyaline cartilage islands. Seventeen patients (85%) were treated surgically, and 8 patients (40%) received adjuvant treatment. Seven patients (35%) were living at last follow-up, 1.8 to 12.5 years after diagnosis, and 8 patients (40%) died between 1.2 and 21.8 years after diagnosis. Conclusions.-Mesenchymal chondrosarcoma presents multiple challenges. Diagnostic pitfalls include inadequate biopsy samples, which may result in sample error. Sox9 has been proposed as a unique marker for mesenchymal chondrosarcoma which may improve diagnostic specificity. Treatment and prognosis vary considerably. Patients who receive surgery and chemotherapy seem to fare better. Multicenter studies with higher sample numbers may improve our understanding of this malignancy.

AB - Context.-Mesenchymal chondrosarcoma is a rare, highgrade malignancy of bone or soft tissue with a unique, biphasic histology and poor prognosis. Because of its rarity and variable length of disease-free survival, the natural history of the disease remains poorly understood. Objective.-To present clinical, radiographic, and histopathologic features of mesenchymal chondrosarcoma from one of the largest case series collected by a single, senior-level bone pathologist. Design.-Twenty cases were reviewed in consultations spanning 45 years. Results.-Eighteen tumors (90%) originated in bone, and 2 tumors (10%) were of extraskeletal origin. Of the skeletal tumors, locations included craniofacial bones (n = 9; 50%), ribs and chest wall (n = 4; 22%), sacrum and spinal elements (n = 3; 17%), and lower extremities (n = 2; 11%), whereas soft tissue tumors were located about the scapula (n = 1; 50%) and lower extremity (n = 1; 50%). Plain radiographs demonstrated calcified, osteolytic lesions with extraosseous extension. Typical histologic features were identified consisting of small, round or spindled cells, interspersed with hyaline cartilage islands. Seventeen patients (85%) were treated surgically, and 8 patients (40%) received adjuvant treatment. Seven patients (35%) were living at last follow-up, 1.8 to 12.5 years after diagnosis, and 8 patients (40%) died between 1.2 and 21.8 years after diagnosis. Conclusions.-Mesenchymal chondrosarcoma presents multiple challenges. Diagnostic pitfalls include inadequate biopsy samples, which may result in sample error. Sox9 has been proposed as a unique marker for mesenchymal chondrosarcoma which may improve diagnostic specificity. Treatment and prognosis vary considerably. Patients who receive surgery and chemotherapy seem to fare better. Multicenter studies with higher sample numbers may improve our understanding of this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=84856036712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856036712&partnerID=8YFLogxK

U2 - 10.5858/arpa.2010-0362-OA

DO - 10.5858/arpa.2010-0362-OA

M3 - Article

VL - 136

SP - 61

EP - 75

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 1

ER -